Abstract
The present review provides a comprehensive analysis of the significance of telomerase reverse transcriptase (TERT) promoter mutations in the progression of anaplastic thyroid cancer (ATC). The significance of these mutations lies in their role in reactivating telomerase, and when combined with BRAF and RAS mutations, they contribute to heightened aggressiveness in ATC. The clinical implications of TERT promoter mutations were discussed, evaluating their potential role as prognostic biomarkers and targets for therapeutic intervention. The present review also emphasizes recent developments in our comprehension of TERT's role in the progression of ATC, offering insights that may guide future investigations focused on improving patient management for this condition.